🇺🇸 Onvansertib in United States
28 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 20 April 2025 – 20 April 2026
- Total reports: 28
Most-reported reactions
- Febrile Neutropenia — 5 reports (17.86%)
- Drug Resistance — 4 reports (14.29%)
- Hyperphosphataemia — 3 reports (10.71%)
- Intestinal Obstruction — 3 reports (10.71%)
- Leukopenia — 3 reports (10.71%)
- Abdominal Abscess — 2 reports (7.14%)
- Abdominal Pain — 2 reports (7.14%)
- Alanine Aminotransferase Increased — 2 reports (7.14%)
- Aspartate Aminotransferase Increased — 2 reports (7.14%)
- Blood Alkaline Phosphatase Increased — 2 reports (7.14%)
Other Other approved in United States
Frequently asked questions
Is Onvansertib approved in United States?
Onvansertib does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Onvansertib in United States?
Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.